NRX-101 receives FDA clearance to enter clinic for cUTI
Dec. 19, 2023
Nrx Pharmaceuticals Inc. has announced FDA clearance of its IND application for the use of NRX-101 (lurasidone hydrochloride/D-cycloserine) for the treatment of complicated urinary tract infections (cUTI).